Issue of Equity

RNS Number : 3456B
Avacta Group PLC
06 January 2015
 



 

Avacta Group plc

("Avacta", the "Group" or the "Company")

 

Issue of Equity

 

Avacta Group plc (AIM: AVCT), a global provider of research reagents, consumables and equipment to the life sciences and animal care markets, today announces that 7,500,000 Ordinary Shares of 0.1p ("new Ordinary Shares") have been issued by the Company pursuant to the exercise of share options.

 

Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 9 January 2015.

 

The total number of Ordinary Shares in issue following the above issue will be 4,975,149,550 each with voting rights.  No Ordinary Shares are held in Treasury.

 

The above figure of 4,975,149,550 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

 

 

Avacta Group plc

www.avacta.com

Alastair Smith, Chief Executive Officer

Tel:  +44 (0) 844 414 0452

Tim Sykes, Chief Financial Officer


 

Numis Securities Limited    

Tel:  +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)


James Black  (Corporate Broking)


 

Walbrook PR Limited

Tel: +44 (0) 20 7933 8780 or avacta@walbrookpr.com

Mike Wort

Mob: +44 (0)7900 608 002

Anna Dunphy

Mob: +44 (0)7876 741 001

 

Avacta Group plc is a global provider of research reagents, consumables and equipment to the life sciences and animal care. Avacta operates through three divisions:

 

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory services, SensiTest, and diagnostic kits, SensiPak.

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

 

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEUVVKRVAAARAR
UK 100

Latest directors dealings